Carla Mouta-Bellum | Finnegan Henderson Farabow Garrett and Dunner Llp

Carla Mouta-Bellum, , Finnegan Henderson Farabow Garrett and Dunner Llp

Carla Mouta-Bellum focuses on drafting and prosecuting patent applications in the fields of biotechnology, biosimilars, and personalized medicine, client counseling, and world-wide patent portfolio lifecycle management. Dr. Mouta-Bellum was a cancer researcher for more than 13 years and has further acquired more than 11 years of experience with patents directed to protecting antibody-related inventions, methods of diagnosis and treatment, transgenic technologies, and metabolic engineering of microorganisms for the production of bio-based polymers. She regularly counsels biotechnology and pharmaceutical clients on patentability, validity, noninfringement, and due diligence opinions. Dr. Mouta-Bellum has worked with clients in licensing negotiations of antibody-based portfolios in clinical trials. She writes regularly on issues of patent eligibility and antibody-related patentability challenges.


EAC 2017 Day 1, Tuesday 31st October 2017 @ 16:50

Patenting a strategically designed antibody-based portfolio in the United States

  • Balancing claim scope with enablement and written description support
  • Obviousness in the U.S. versus Europe and the rest of the world
  • Lifecycle management for antibody-based inventions

back to speakers